Announcements

Job Offers

Top 5 -yesterday

Top 5 -last week

Top 5 -last month

German MMJ grower receives GMP certificate

Demecan has been granted a manufacturing license in accordance with §13 AMG (German Medicines Act) and GMP (Good Manufacturing Practice) certification for its production facility near Dresden. The GMP manufacturing license granted by the Saxon state authority allows Demecan to produce dried cannabis as medicinal products with immediate effect.



The internationally recognized certification ensures the high quality of medicinal products over the entire manufacturing process. GMP stands for "Good Manufacturing Practice" and means the highest manufacturing standards, which are independently monitored and inspected by pharmaceutical authorities.



Dr. Adrian Fischer, a medical doctor and Demecan's managing director, is pleased: "GMP certification is the strictest standard that manufacturers have to meet, as high quality is expected from pharmaceuticals. The fact that we now hold this certificate in
our hands is an extraordinary milestone in Demecan's young history and an important one for the development of the German Cannabis Center in Saxony. As founder and CEO, I am very grateful for the great team with which we managed to pass the inspection only six weeks after the completion of our building. And we have now fully
ramped up production capacity. That's an incredible accomplishment, and we'll celebrate that appropriately as soon as the Covid situation allows."



The way is now clear for the first cannabis flowers "Made in Germany". Demecan still plans to deliver the first products to the state cannabis agency and through it to pharmacies in Q1/22. The in-house produced flower will then complement the existing
Florestura flower portfolio.



With GMP certification, Demecan can now produce its own medicines and test them for efficacy through clinical trials. The research activity is important as there is still prejudice against cannabis in medicine. In order to pave the way for further therapeutic areas and to further reduce the prescription hurdles for patients, further research is therefore needed both nationally and internationally. Demecan supports this and plans to start its own study this year.

For more information:
Demecan
info@demecan.de  
demecan.de  




Publication date:



Receive the daily newsletter in your email for free | Click here


Other news in this sector:


Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber